Improving Hepatitis C Treatment in Injection Drug Users

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

111 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-30

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection.

Hypothesis: An intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs will increase access by integrating HCV medical care into a substance abuse treatment program.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatitis C Treatment in Underserved Populations

NCT01717560

Chronic Hepatitis C Illicit Drug Use

UNKNOWN NA

HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention

NCT03242655

Hepatitis C Substance Use Disorders

COMPLETED NA

A Trial to Reduce Hepatitis C Among Injection Drug Users - 1

NCT00218192

HCV Negative Status HCV Risk Behavior

COMPLETED PHASE3

Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)

NCT03214679

Hepatitis C People Who Inject Drugs PWID +1 more

COMPLETED NA

Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users

NCT00194480

Substance-Related Disorders Hepatitis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall goal of the proposed health services research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection. This will be done by testing an intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs. This intervention will increase access by integrating HCV medical care into a substance abuse treatment program. HCV infection is endemic among IDUs, and is associated with significant medical morbidity. While antiviral treatments are improving rapidly, providing HCV medical care for IDUs remains problematic for a number of reasons. IDUs often do not have adequate access to HCV diagnosis and treatment services, and they may have co-morbid psychiatric diagnoses that affect the ability to withstand the demands of HCV treatment. Therefore, this study will also examine psychiatric disorders and psychiatric symptoms in IDUs who are infected with Hepatitis C virus.

The proposed project is a five-year program consisting of a controlled clinical trial, studying 220 patients with HCV infection enrolled in methadone maintenance treatment (MMT). The HCV Medical Care Study is a randomized trial to test the efficacy of On-site HCV Medical Care provided at the MMT program versus Off-site care at the Gastroenterology (GI) Clinic. HCV antibody positive MMT patients (N=220) will be randomly assigned to receive HCV medical services either through an integrated delivery model located on-site in the MMT clinic, or through usual off-site referral to the GI Clinic. The main outcomes will be the rates of attaining SVR and completion of HCV treatment, as well as other measures of HCV-related health outcomes and quality of life. Participants will be evaluated for Axis I psychiatric diagnoses and will complete psychiatric measures at monthly intervals throughout the study. Psychiatric diagnosis will be made using the Structured Psychiatric Interview for the DSM-IV (SCID) and psychiatric symptom severity will be assessed for depression, mania, anxiety, and psychosis. Drug use measures, and quality of life measures will also be obtained. These data are expected to yield new knowledge about the efficacy of providing on-site HVC medical care in substance abuse treatment programs. They will provide a comparison of psychiatric diagnoses and psychiatric symptom presentation in HCV positive IDUs who choose to receive HCV treatment and those who do not choose to follow through with HCV treatment and will describe changes in psychiatric symptoms before, during, and after HCV medical care. Finally, the studies will also provide information about the influence of psychiatric symptoms and drug and alcohol use on HCV medical outcomes such as treatment completion and SVR.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C Liver Diseases Drug Abuse Alcoholism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

On-site (MMT Clinic) HCV evaluation and treatment

Group Type EXPERIMENTAL

Pegylated Interferon and Ribavirin

Intervention Type DRUG

Both groups with receive the same medical intervention but offered at different locations

Psychosocial

Intervention Type BEHAVIORAL

Assessment of the likelihood of HCV treatment initiation and completion

On-site (MMT Clinic) HCV evaluation and treatment

Intervention Type BEHAVIORAL

Standard HCV treatment with Pegylated Interferon and Ribavirin

2

Off-site (GI Clinic) HCV evaluation and treatment

Group Type ACTIVE_COMPARATOR

Pegylated Interferon and Ribavirin

Intervention Type DRUG

Both groups with receive the same medical intervention but offered at different locations

Psychosocial

Intervention Type BEHAVIORAL

Assessment of the likelihood of HCV treatment initiation and completion

Off-site HCV evaluation and treatment

Intervention Type BEHAVIORAL

Standard HCV treatment with Pegylated Interferon and Ribavirin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pegylated Interferon and Ribavirin

Both groups with receive the same medical intervention but offered at different locations

Intervention Type DRUG

Psychosocial

Assessment of the likelihood of HCV treatment initiation and completion

Intervention Type BEHAVIORAL

On-site (MMT Clinic) HCV evaluation and treatment

Standard HCV treatment with Pegylated Interferon and Ribavirin

Intervention Type BEHAVIORAL

Off-site HCV evaluation and treatment

Standard HCV treatment with Pegylated Interferon and Ribavirin

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18-65 years of age.
2. Enrolled in outpatient methadone maintenance treatment for greater than 3 months.
3. Hepatitis C RNA positive.
4. Willingness to accept HCV treatment.
5. Subject has non-VA (Veteran's Administration) medical insurance or is willing to bear any and all expenses associated with Hepatitis C medical treatment.

Exclusion Criteria

1. In need of inpatient drug or alcohol detoxification.
2. Currently receiving the standard Hepatitis C treatment
3. Unable to give adequate informed consent.
4. Pregnant, nursing, or planning to become pregnant during HCV treatment or within 6 months following completion of treatment.
5. Male subject who has a female sexual partner who is pregnant or planning to become pregnant at any time during HCV treatment or within 6 months following completion of treatment.
6. Female subject or male subject who has a female sexual partner who is of child bearing years and not using two medically approved forms of contraception.
7. Subject has made a commitment to attend residential care psychiatric or drug/alcohol rehabilitation, which would lead to unavailability to attend regularly scheduled medical care and research visits.
8. Subject did not attend all required screening appointments.
9. Subject has a legal proceeding whose outcome may lead to incarceration within 3 months of intake.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No